Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03844048 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
A Phase 3 study of Cancer and Multiple Myeloma, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT03844048: Active Phase 3 study of Cancer and Multiple Myeloma, sponsored by AbbVie.
NCT03844048 is a Phase 3 study of Cancer and Multiple Myeloma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 165 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03844048, a Phase 3 study of Cancer and Multiple Myeloma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization,
Conditions Studied
Interventions
- DRUG Venetoclax
Study Locations (20)
New South Wales
- Royal Prince Alfred Hospital /ID# 239557 - Camperdown
- St George Hospital /ID# 225589 - Kogarah
- Liverpool Hospital /ID# 225591 - Liverpool
Western Australia
- Fiona Stanley Hospital /ID# 239480 - Murdoch
- Perth Blood Institute Ltd /ID# 225592 - Nedlands
Arizona
- University of Arizona Cancer Center - Tucson /ID# 210548 - Tucson
California
- UCLA Santa Monica Hematology Oncology /ID# 210551 - Los Angeles
Illinois
- Ingalls Memorial Hosp /ID# 210553 - Harvey
Massachusetts
- Dana-Farber Cancer Institute /ID# 215360 - Boston
Michigan
- University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132 - Ann Arbor
New Hampshire
- Dartmouth-Hitchcock Medical Center /ID# 210555 - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
What the registry record for NCT03844048 still lists
NCT03844048 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Venetoclax is the first listed.
NCT03844048 names 20 study sites across 17 states, led by New South Wales, Western Australia, Arizona.
Frequently Asked Questions
What is clinical trial NCT03844048 about?
NCT03844048 is a clinical study titled "An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial". The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
What is the current status of trial NCT03844048?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2019-09-06. Estimated completion is 2027-08.
What conditions does trial NCT03844048 study?
This clinical trial studies the following conditions: Cancer, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT03844048?
The interventions under investigation include: Venetoclax (DRUG).
Who is sponsoring clinical trial NCT03844048?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03844048 being conducted?
This trial has 20 study locations across Arizona, California, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03844048's enrollment target sits among peer trials
165 256th of 615 higher than 359 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
- NCT04458584 · 165 participants
Restoration of Thumb Strength and Function in Basal Joint Arthritis: A Comparative Effectiveness Trial (RESTART)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI